Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FRESENIUS SE & CO. KGAA

(FRE)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 01/24 03:59:59 pm
35.678 EUR   -1.84%
01/19European ADRs Move Higher in Wednesday Trading
MT
01/18European ADRs Move Lower in Tuesday Trading
MT
01/17Fresenius Kabi is committed to achieving Net Zero emissions by 2045
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fresenius : Helios acquires oncological center and ophthalmic clinic in Colombia

11/22/2021 | 05:04am EST

Press Release

November 22, 2021

Steffen Rinas

Corporate Communications

Fresenius SE & Co. KGaA

Else-Kröner-Straße 1

61352 Bad Homburg

Germany

  1. +49 6172 608-6698 F +49 6172 608-2294 steffen.rinas@fresenius.com www.fresenius.com

Fresenius Helios acquires oncological center and ophthalmic

clinic in Colombia

Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, has signed agreements to acquire Centro Oncológico de Antioquia (COA) and Clínica Clofán, further expanding the company's presence in Colombia. The clinics, located in Colombia's second largest city Medellín, will become part of Quirónsalud's existing healthcare network in the country, which already comprises six hospitals and ten diagnostic centers.

COA is specialized in the diagnosis and treatment of cancer. It has 75 beds, four operating rooms, and specialized centers for nuclear medicine, radiotherapy and bone marrow transplants. Clínica Clofán is the second largest ophthalmic center in the city, with ten operating rooms and further dedicated facilities for treating even severe ophthalmic diseases and performing complex procedures.

Both clinics offer state-of-the-art medical standards and technology to their patients and are regarded as leading medical facilities with highly renowned physicians. Together they generate sales of around €30 million.

The acquisition is another important step in strengthening Fresenius Helios' presence in the growing and consolidating healthcare services markets in Latin America.

Page 1/2

The transaction is expected to close in the first quarter of 2022, pending anti-trust clearance of the Colombian authorities. Fresenius Helios expects the acquisition to be accretive to Fresenius' Group net income1 already in fiscal year 2022.

# # #

Fresenius is a global health care group, providing products and services for dialysis, hospital and outpatient medical care. In 2020, Group sales were €36.3 billion. On September 30, 2021, the Fresenius Group had 314,852 employees worldwide.

For more information visit the Company's website at www.fresenius.com. Follow us on social media: www.fresenius.com/socialmedia

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA

Registered Office: Bad Homburg, Germany

Commercial Register: Amtsgericht Bad Homburg, HRB 11852

Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE

Registered Office: Bad Homburg, Germany

Commercial Register: Amtsgericht Bad Homburg, HRB 11673

Management Board: Stephan Sturm (Chairman), Dr. Sebastian Biedenkopf, Dr. Francesco De Meo, Rachel Empey, Rice Powell, Michael Sen, Dr. Ernst Wastler

Chairman of the Supervisory Board: Wolfgang Kirsch

1 Net income attributable to shareholders of Fresenius SE & Co. KGaA

Page 2/2

Disclaimer

Fresenius SE & Co. KGaA published this content on 22 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 November 2021 10:03:10 UTC.


ę Publicnow 2021
All news about FRESENIUS SE & CO. KGAA
01/19European ADRs Move Higher in Wednesday Trading
MT
01/18European ADRs Move Lower in Tuesday Trading
MT
01/17Fresenius Kabi is committed to achieving Net Zero emissions by 2045
AQ
01/17FRESENIUS SE : JP Morgan remains Neutral
MD
01/14European ADRs Move Higher in Friday Trading
MT
01/13Thyssenkrupp's hydrogen business gets KGaA structure
RE
01/11FRESENIUS SE : JP Morgan gives a Neutral rating
MD
01/10FRESENIUS : Helios acquires majority stake in U.S. fertility center
PU
01/04FRESENIUS : ODDO BHF Forum 2022
PU
01/04FRESENIUS SE : JP Morgan reaffirms its Neutral rating
MD
More news
Analyst Recommendations on FRESENIUS SE & CO. KGAA
More recommendations
Financials
Sales 2021 37 312 M 42 260 M 42 260 M
Net income 2021 1 825 M 2 067 M 2 067 M
Net Debt 2021 22 585 M 25 580 M 25 580 M
P/E ratio 2021 10,8x
Yield 2021 2,44%
Capitalization 19 808 M 22 410 M 22 435 M
EV / Sales 2021 1,14x
EV / Sales 2022 1,05x
Nbr of Employees 314 852
Free-Float 73,4%
Chart FRESENIUS SE & CO. KGAA
Duration : Period :
Fresenius SE & Co. KGaA Technical Analysis Chart | FRE | DE0005785604 | MarketScreener
Technical analysis trends FRESENIUS SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 35,47 €
Average target price 48,62 €
Spread / Average Target 37,1%
EPS Revisions
Managers and Directors
Stephan Sturm President & Chief Executive Officer
Rachel Clare Empey Chief Financial Officer
Wolfgang Kirsch Chairman-Supervisory Board
Sebastian Biedenkopf Head-Legal & Human Resources Director
Klaus-Peter MŘller Independent Member-Supervisory Board